You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameCosyntropin
Accession NumberDB01284
Typebiotech
Groupsapproved
Description

A synthetic peptide that is identical to the 24-amino acid segment at the N-terminal of adrenocorticotropic hormone. ACTH (1-24), a segment similar in all species, contains the biological activity that stimulates production of corticosteroids in the adrenal cortex.

Protein structureNo structure small
Protein chemical formulaC136H210N40O31S
Protein average weight2933.4370
Sequences
>ACTH(1-24)
SYSMEHFRWGKPVGKKRRPVKVYP
Download FASTA Format
Synonyms
SynonymLanguageCode
Adrenocorticotropic hormone 1-24Not AvailableNot Available
alpha(1-24)-CorticotrophinNot AvailableNot Available
ATCH (1-24)Not AvailableNot Available
beta(1-24)-CorticotrophinNot AvailableNot Available
Corticotropin-(1-24)Not AvailableNot Available
Corticotropin-(1-24) tetracosapeptideNot AvailableNot Available
CosyntropinNot AvailableNot Available
SerTyrSerMetGluHisPheArgTrpGlyLysProValGlyLysLysArgArgProValLysValTyrProNot AvailableNot Available
SYSMEHFRWGKPVGKKRRPVKVYPNot AvailableNot Available
TetracosactideNot AvailableNot Available
SaltsNot Available
Brand names
NameCompany
CortrosynNot Available
Synacthen depotNot Available
Brand mixturesNot Available
Categories
CAS number16960-16-0
Taxonomy
KingdomOrganic Compounds
SuperclassOrganic Acids
ClassCarboxylic Acids and Derivatives
SubclassAmino Acids, Peptides, and Analogues
Direct parentPeptides
Alternative parentsNot Available
SubstituentsNot Available
Classification descriptionNot Available
Pharmacology
IndicationFor use as a diagnostic agent in the screening of patients presumed to have adrenocortical insufficiency.
PharmacodynamicsCosyntropin exhibits the full corticosteroidogenic activity of natural ACTH. Various studies have shown that the biologic activity of ACTH resides in the N- terminal portion of the molecule and that the 1-20 amino acid residue is the minimal sequence retaining full activity. Partial or complete loss of activity is noted with progressive shortening of the chain beyond 20 amino acid residue. For example, the decrement from 20 to 19 results in a 70% loss of potency. The pharmacologic profile of Cosyntropin is similar to that of purified natural ACTH. It has been established that 0.25 mg of Cosyntropin will stimulate the adrenal cortex maximally and to the same extent as 25 units of natural ACTH. Cosyntropin has less immunogenic activity than ACTH because the amino acid sequence having most of the antigenic activity of ACTH, i.e., amino acids 25-39, is not present in cosyntropin. The extra-adrenal effects which natural ACTH and Cosyntropin have in common include increased melanotropic activity, increased growth hormone secretion and an adipokinetic effect. These are considered to be without physiological or clinical significance.
Mechanism of actionCosyntropin combines with a specific receptor in the adrenal cell plasma membrane and, in patients with normal adrenocortical function, stimulates the initial reaction involved in the synthesis of adrenal steroids (including cortisol, cortisone, weak androgenic substances, and a limited quantity of aldosterone) from cholesterol by increasing the quantity of the substrate within the mitochondria. Cosyntropin does not significantly increase plasma cortisol concentration in patients with primary or secondary adrenocortical insufficiency.
AbsorptionRapidly absorbed following intramuscular administration.
Volume of distributionNot Available
Protein bindingNot Available
Metabolism
Route of eliminationNot Available
Half lifeAbout 15 minutes following intravenous administration.
ClearanceNot Available
ToxicityNot Available
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Pharmacoeconomics
Manufacturers
  • Amphastar pharmaceuticals inc
  • Bioniche pharma usa llc
  • Sandoz canada inc
Packagers
Dosage forms
FormRouteStrength
LiquidIntramuscular
Powder, for solutionIntravenous
Prices
Unit descriptionCostUnit
Cortrosyn 0.25 mg vial127.9USDvial
Cosyntropin 0.25 mg/ml119.91USDml
Cosyntropin 0.25 mg vial115.1USDvial
Synacthen Depot 1 mg/vial34.77USDvial
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
Statesolid
Experimental PropertiesNot Available
References
Synthesis ReferenceNot Available
General ReferenceNot Available
External Links
ResourceLink
PharmGKBPA164749052
Drug Product Database22381
RxListhttp://www.rxlist.com/cgi/generic/cortrosyn.htm
Drugs.comhttp://www.drugs.com/cdi/cosyntropin.html
WikipediaCosyntropin
ATC CodesH01AA02
AHFS Codes
  • 68:28.00
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
Interactions
Drug InteractionsSearched, but no interactions found.
Food InteractionsNot Available

Targets

1. Adrenocorticotropic hormone receptor

Kind: protein

Organism: Human

Pharmacological action: yes

Actions: antagonist

Components

Name UniProt ID Details
Adrenocorticotropic hormone receptor Q01718 Details

References:

  1. Schwerin M, Kanitz E, Tuchscherer M, Brussow KP, Nurnberg G, Otten W: Stress-related gene expression in brain and adrenal gland of porcine fetuses and neonates. Theriogenology. 2005 Mar 1;63(4):1220-34. Pubmed
  2. Mehrabani PA, Bassett JR: Adrenocorticotropin binding sites in rat cardiac tissue. Pharmacol Biochem Behav. 1990 Jan;35(1):99-103. Pubmed
  3. Moraes RB, Czepielewski MA, Friedman G: Cortisol variation after low-dose Cortrosyn test. Crit Care Med. 2010 Jul;38(7):1612-3. Pubmed
  4. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. Pubmed

Comments
comments powered by Disqus
Drug created on May 23, 2007 21:46 / Updated on September 03, 2011 16:33